Lv7
4840 积分 2022-11-04 加入
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC
12小时前
已完结
NSCLC: Five trials to watch
13小时前
已完结
Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy
13小时前
已完结
Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma
14小时前
已完结
Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations
14小时前
已完结
KRAS Mutation Status in Non-Small Cell Lung Cancer Distribution Across Occupational Categories
15小时前
已关闭
Identification and validation of natural product-based KRASG12D inhibitors through structure-based virtual screening, molecular dynamics simulation, and in vitro studies
15小时前
已完结
Zoldonrasib Deemed Safe, Effective in KRAS G12D-mutant NSCLC
17小时前
已关闭
MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells
17小时前
已完结
Flourishing innovation in KRAS targeting: Recent advances in medicinal chemistry strategies and future perspectives
17小时前
已完结
皖公网安备34019202002308
